Advertisement

Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study)

Published:November 05, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.10.037
      An increasing hemoglobin A1c (HbA1c) level portends an adverse cardiovascular prognosis; however, the association between glycemic control, platelet reactivity, and outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is unknown. We sought to investigate whether HbA1c levels are associated with high platelet reactivity (HPR) in patients loaded with clopidogrel and aspirin, thereby constituting an argument for intensified antiplatelet therapy in patients with poor glycemic control. In the prospective, multicenter Assessment of Dual Antiplatelet Therapy With Drug Eluting Stents registry, HbA1c levels were measured as clinically indicated in 1,145 of 8,582 patients, stratified by HbA1c <6.5% (n = 551, 48.12%), 6.5% to 8.5% (n = 423, 36.9%), and >8.5% (n = 171, 14.9%). HPR on clopidogrel and aspirin was defined after PCI as P2Y12 reaction units (PRU) >208 and aspirin reaction units >550, respectively. HPR on clopidogrel was frequent (48.3%), whereas HPR on aspirin was not (3.9%). Patients with HbA1c >8.5% were younger, more likely non-Caucasian, had a greater body mass index, and more insulin-treated diabetes and acute coronary syndromes. Proportions of PRU >208 (42.5%, 50.2%, and 62.3%, p <0.001) and rates of definite or probable stent thrombosis (ST; 0.9%, 2.7%, and 4.2%, p = 0.02) increased progressively with HbA1c groups. Clinically relevant bleeding was greatest in the intermediate HbA1c group (8.2% vs 13.1% vs 9.5%, p = 0.04). In adjusted models that included PRU, high HbA1c levels (>8.5) remained associated with ST (hazard ratio 3.92, 95% CI 1.29 to 12.66, p = 0.02) and cardiac death (hazard ratio 4.24, 95% CI 1.41 to 12.70) but not bleeding at 2-year follow-up. There was no association between aspirin reaction units >550 and HbA1c levels. In conclusion, in this large-scale study, HbA1c and HPR were positively associated, but the clinical effect on adverse outcome was driven by poor glycemic control, which predicted ST and cardiac death after PCI regardless of PRU levels, warranting efforts to improve glycemic control after DES implantation in patients with diabetes mellitus.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schneider D.J.
        Factors contributing to increased platelet reactivity in people with diabetes.
        Diabetes Care. 2009; 32: 525-527
        • Geisler T.
        • Langer H.
        • Wydymus M.
        • Gohring K.
        • Zurn C.
        • Bigalke B.
        • Stellos K.
        • May A.E.
        • Gawaz M.
        Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.
        Eur Heart J. 2006; 27: 2420-2425
        • Gurbel P.A.
        • Bliden K.P.
        • Samara W.
        • Yoho J.A.
        • Hayes K.
        • Fissha M.Z.
        • Tantry U.S.
        Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study.
        J Am Coll Cardiol. 2005; 46: 1827-1832
        • Hochholzer W.
        • Trenk D.
        • Bestehorn H.P.
        • Fischer B.
        • Valina C.M.
        • Ferenc M.
        • Gick M.
        • Caputo A.
        • Buttner H.J.
        • Neumann F.J.
        Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
        J Am Coll Cardiol. 2006; 48: 1742-1750
        • Price M.J.
        • Angiolillo D.J.
        • Teirstein P.S.
        • Lillie E.
        • Manoukian S.V.
        • Berger P.B.
        • Tanguay J.F.
        • Cannon C.P.
        • Topol E.J.
        Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
        Circulation. 2011; 124: 1132-1137
        • Campo G.
        • Fileti L.
        • de Cesare N.
        • Meliga E.
        • Furgieri A.
        • Russo F.
        • Colangelo S.
        • Brugaletta S.
        • Ferrari R.
        • Valgimigli M.
        Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
        J Am Coll Cardiol. 2010; 56: 1447-1455
        • Patti G.
        • Nusca A.
        • Mangiacapra F.
        • Gatto L.
        • D'Ambrosio A.
        • Di Sciascio G.
        Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
        J Am Coll Cardiol. 2008; 52: 1128-1133
        • Marcucci R.
        • Gori A.M.
        • Paniccia R.
        • Giusti B.
        • Valente S.
        • Giglioli C.
        • Buonamici P.
        • Antoniucci D.
        • Abbate R.
        • Gensini G.F.
        Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
        Circulation. 2009; 119: 237-242
        • Andersson C.
        • van Gaal L.
        • Caterson I.D.
        • Weeke P.
        • James W.P.
        • Coutinho W.
        • Finer N.
        • Sharma A.M.
        • Maggioni A.P.
        • Torp-Pedersen C.
        Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes.
        Diabetologia. 2012; 55: 2348-2355
        • Xu L.
        • Chan W.M.
        • Hui Y.F.
        • Lam T.H.
        Association between HbA1c and cardiovascular disease mortality in older Hong Kong Chinese with diabetes.
        Diabet Med. 2012; 29: 393-398
        • Park K.W.
        • Park J.J.
        • Jeon K.H.
        • Kang S.H.
        • Oh I.Y.
        • Yang H.M.
        • Cho H.J.
        • Lee H.Y.
        • Kang H.J.
        • Koo B.K.
        • Oh B.H.
        • Park Y.B.
        • Kim H.S.
        Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.
        Cardiovasc Ther. 2012; 30: 5-11
        • Ang L.
        • Palakodeti V.
        • Khalid A.
        • Tsimikas S.
        • Idrees Z.
        • Tran P.
        • Clopton P.
        • Zafar N.
        • Bromberg-Marin G.
        • Keramati S.
        • Mahmud E.
        Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel.
        J Am Coll Cardiol. 2008; 52: 1052-1059
        • Wiviott S.D.
        • Braunwald E.
        • Angiolillo D.J.
        • Meisel S.
        • Dalby A.J.
        • Verheugt F.W.
        • Goodman S.G.
        • Corbalan R.
        • Purdy D.A.
        • Murphy S.A.
        • McCabe C.H.
        • Antman E.M.
        Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
        Circulation. 2008; 118: 1626-1636
        • James S.
        • Angiolillo D.J.
        • Cornel J.H.
        • Erlinge D.
        • Husted S.
        • Kontny F.
        • Maya J.
        • Nicolau J.C.
        • Spinar J.
        • Storey R.F.
        • Stevens S.R.
        • Wallentin L.
        Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
        Eur Heart J. 2010; 31: 3006-3016
        • Baber U.
        • Bander J.
        • Karajgikar R.
        • Yadav K.
        • Hadi A.
        • Theodoropolous K.
        • Gukathasan N.
        • Roy S.
        • Sayeneni S.
        • Scott S.A.
        • Kovacic J.C.
        • Yu J.
        • Sartori S.
        • Mehran R.
        • Uribarri J.
        • Badimon J.J.
        • Muntner P.
        • Moreno P.
        • Kini A.S.
        • Sharma S.K.
        Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity.
        Thromb Haemost. 2013; 110: 118-123
        • Mangiacapra F.
        • Peace A.J.
        • Wijns W.
        • Barbato E.
        Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel.
        J Thromb Thrombolysis. 2011; 32: 54-58
        • Singer J.
        • Weissler Snir A.
        • Leshem-Lev D.
        • Rigler M.
        • Kornowski R.
        • Lev E.I.
        Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes.
        Thromb Res. 2014; 134: 121-124
        • Stone G.W.
        • Witzenbichler B.
        • Weisz G.
        • Rinaldi M.J.
        • Neumann F.J.
        • Metzger D.C.
        • Henry T.D.
        • Cox D.A.
        • Duffy P.L.
        • Mazzaferri E.
        • Gurbel P.A.
        • Xu K.
        • Parise H.
        • Kirtane A.J.
        • Brodie B.R.
        • Mehran R.
        • Stuckey T.D.
        Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
        Lancet. 2013; 382: 614-623
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • Steg P.G.
        • Morel M.A.
        • Mauri L.
        • Vranckx P.
        • McFadden E.
        • Lansky A.
        • Hamon M.
        • Krucoff M.W.
        • Serruys P.W.
        • Academic Research C.
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Mehta S.R.
        • Yusuf S.
        • Peters R.J.
        • Bertrand M.E.
        • Lewis B.S.
        • Natarajan M.K.
        • Malmberg K.
        • Rupprecht H.
        • Zhao F.
        • Chrolavicius S.
        • Copland I.
        • Fox K.A.
        Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
        Lancet. 2001; 358: 527-533
        • Angiolillo D.J.
        • Badimon J.J.
        • Saucedo J.F.
        • Frelinger A.L.
        • Michelson A.D.
        • Jakubowski J.A.
        • Zhu B.
        • Ojeh C.K.
        • Baker B.A.
        • Effron M.B.
        A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy in diabetes MellitUS (OPTIMUS)-3 Trial.
        Eur Heart J. 2011; 32: 838-846
        • Laine M.
        • Frere C.
        • Toesca R.
        • Berbis J.
        • Barnay P.
        • Pansieri M.
        • Michelet P.
        • Bessereau J.
        • Camilleri E.
        • Ronsin O.
        • Helal O.
        • Paganelli F.
        • Dignat-George F.
        • Bonello L.
        Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
        Thromb Haemost. 2014; 111: 273-278
        • Pankert M.
        • Quilici J.
        • Loundou A.D.
        • Verdier V.
        • Lambert M.
        • Deharo P.
        • Bonnet G.
        • Gaborit B.
        • Morange P.E.
        • Valero R.
        • Dutour A.
        • Bonnet J.L.
        • Alessi M.C.
        • Cuisset T.
        Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
        Am J Cardiol. 2014; 113: 54-59
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • Cannon C.P.
        • Emanuelsson H.
        • Held C.
        • Horrow J.
        • Husted S.
        • James S.
        • Katus H.
        • Mahaffey K.W.
        • Scirica B.M.
        • Skene A.
        • Steg P.G.
        • Storey R.F.
        • Harrington R.A.
        • Investigators P.
        • Freij A.
        • Thorsen M.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Gaglia Jr., M.A.
        • Torguson R.
        • Pakala R.
        • Xue Z.
        • Sardi G.
        • Mahmoudi M.
        • Suddath W.O.
        • Kent K.M.
        • Satler L.F.
        • Pichard A.D.
        • Waksman R.
        Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity.
        Am J Cardiol. 2011; 108: 766-771
        • Jaitner J.
        • Stegherr J.
        • Morath T.
        • Braun S.
        • Bernlochner I.
        • Schomig A.
        • Kastrati A.
        • Sibbing D.
        Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients.
        Thromb Haemost. 2011; 105: 107-112
        • Brar S.S.
        • ten Berg J.
        • Marcucci R.
        • Price M.J.
        • Valgimigli M.
        • Kim H.S.
        • Patti G.
        • Breet N.J.
        • DiSciascio G.
        • Cuisset T.
        • Dangas G.
        Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.
        J Am Coll Cardiol. 2011; 58: 1945-1954
        • Gerstein H.C.
        • Miller M.E.
        • Ismail-Beigi F.
        • Largay J.
        • McDonald C.
        • Lochnan H.A.
        • Booth G.L.
        • ACCORD Study Group
        Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.
        Lancet. 2014; 384: 1936-1941
        • Gerstein H.C.
        • Miller M.E.
        • Byington R.P.
        • Goff Jr., D.C.
        • Bigger J.T.
        • Buse J.B.
        • Cushman W.C.
        • Genuth S.
        • Ismail-Beigi F.
        • Grimm Jr., R.H.
        • Probstfield J.L.
        • Simons-Morton D.G.
        • Friedewald W.T.
        • Action to Control Cardiovascular Risk in Diabetes Study Group
        Effects of intensive glucose lowering in type 2 diabetes.
        N Engl J Med. 2008; 358: 2545-2559